Osteotropism of NETs: Role of the SDF1/CXCR4 Axis in Regulating EMT Abstract #1520

Introduction: NETs metastasize to the bone in up to 20% of patients. The SDF1/CXCR4 axis is a key determinant of osteotropism, and we showed that NETs overexpressing CXCR4 are more likely to develop bone metastases.
Aim(s): To explore the biologic mechanisms underlying CXCR4-driven NET bone metastases.
Materials and methods: BON1, QGP1, CM, H727 and CNDT2.5 cells were evaluated in their CXCR4 expression by flow cytometry. Migration and invasion towards the bone or SDF1-conditioned medium were assessed by functional assays. Transcription and expression levels of EMT-related genes were assessed by RT-PCR and immunocytochemistry before and after SDF1 treatment. Secretion of SDF1 was studied by ELISA. Confocal microscopy and WB were used to investigate the subcellular distribution of CXCR4.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Valeria Simone
Keywords: emt, cxcr4

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1847 CXCR4 Inhibition by Ulocuplumab Prevents EMT of pNET Cells in Vitro
Introduction: Neuroendocrine tumors (NETs) overexpress CXCR4. We have previously shown that stimulation of CXCR4 by its ligand SDF-1 promotes the epithelial-mesenchymal transition (EMT) and increases distant tumor spread. Ulocuplumab (Ulo) is a fully human IgG4 mAb designed to inhibit the binding of CXCR4 to SDF-1.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr. Mauro Cives
Keywords: pNET, CXCR4, EMT, Ulocuplumab
#908 Role of Epithelial-to-Mesenchymal Transition Markers in Predicting Bone and Visceral Metastases from NETs
Introduction: Epithelial-to-mesenchymal transition (EMT) of tumor cells has been recently postulated as a pivotal mechanism driving metastatic spread.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Valeria Simone
Keywords: EMT, biomarker
#2022 CXCR4 Expression on Circulating Tumor Cells (CTCs) and Their Association with Bone Metastases in Patients with Neuroendocrine Tumors (NET)
Introduction: Bone metastases have been described in up to 32% of NET patients and are associated with a worse clinical outcome. Overexpression of CXCR4 in primary tumors appears predictive of skeletal involvement.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Francesca Maria Rizzo
Keywords: CTC, CXCR4, bone
#833 The Chemokine Receptor CXCR4 – Differential Expression in Bronchopulmonary Neuroendocrine Neoplasms
Introduction: The CXCR4 is a plasma membrane chemokine receptor, which is involved in organogenesis, hematopoiesis and inflammation. Additionally, an over-expression is described for many neoplastic tissues. Here, an involvement in tumor progression, metastasis, adaptation to hypoxia and in stem cell survival is postulated.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Christiane Anne Reimann
#3030 Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma
Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dijie Liu